Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 3, Issue -, Pages -Publisher
BMC
DOI: 10.1186/1756-8722-3-8
Keywords
-
Categories
Funding
- National Cancer Institute of Canada
- Cancer Research Society
- Canadian Institutes for Health Research
Ask authors/readers for more resources
The Ras-dependent Raf/MEK/ERK1/2 mitogen-activated protein (MAP) kinase signaling pathway is a major regulator of cell proliferation and survival. Not surprisingly, hyperactivation of this pathway is frequently observed in human malignancies as a result of aberrant activation of receptor tyrosine kinases or gain-of-function mutations in RAS or RAF genes. Components of the ERK1/2 pathway are therefore viewed as attractive candidates for the development of targeted therapies of cancer. In this article, we briefly review the basic research that has laid the groundwork for the clinical development of small molecules inhibitors of the ERK1/2 pathway. We then present the current state of clinical evaluation of MEK1/2 inhibitors in cancer and discuss challenges ahead.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available